In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ribozyme closes $48mm private financing

Executive Summary

Ribozyme Pharmaceuticals (nucleic acid technologies) closed a $48mm private financing of 145.45mm common shares priced at $0.33 each (a 22% premium to market average) and five-year warrants to buy 30mm more common shares at $0.42. Investors (and their post-offering stakes in the company) are Sprout Group (41.8%), Venrock Associates (18.9%), Oxford Bioscience (14.2%), Techno Venture Management (9.2%), and Granite Global Ventures (fund sponsored by Venrock, Singapore Economic Development Board, and U.S. Bancorp Piper Jaffray) (3.7%).
Deal Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies